The Smart Inhalers Market is changing the traditional approach to asthma and COPD management by introducing connected monitoring capabilities into inhalation therapy. Smart inhalers can record medication use, provide reminders, and transmit relevant information through digital platforms. Market Research Future reports that COPD represented 54.3% of smart inhaler market revenue in 2025, while asthma is expected to expand at a 13.9% CAGR during 2026–2035.

Medication adherence is one of the most important challenges in respiratory disease management. Patients may miss doses, use medication incorrectly, or have difficulty remembering their treatment schedules. Smart inhalers can address these problems through automated reminders and usage tracking.

For COPD patients, continuous adherence monitoring can provide valuable information about treatment behavior. Healthcare professionals can identify changes in medication use and potentially intervene before symptoms become more severe. This approach supports the broader shift toward preventive and personalized healthcare.

Asthma management can also benefit from connected inhalation technology. Patients can receive notifications about scheduled medication and maintain digital records of their inhaler use. When environmental information such as air quality or pollen levels is incorporated into digital platforms, patients may receive more relevant information about potential respiratory triggers.

AI-enabled analytics could further improve disease management. Algorithms can evaluate medication patterns, symptom information, and environmental conditions to identify trends associated with exacerbations. Market Research Future highlights AI-enabled adherence analytics as one of the key growth drivers for the industry.

Smart inhalers may also strengthen communication between patients and healthcare professionals. Instead of relying exclusively on patient recollection during consultations, clinicians can access digital adherence information when available. This can support more informed treatment discussions and help identify whether poor outcomes are associated with medication adherence, technique, or other factors.

Homecare is another important area of opportunity. As healthcare systems increasingly emphasize remote monitoring, connected inhalers can become part of broader home-based respiratory care programs. Patients may be able to receive ongoing support without making frequent hospital visits.

The technology could be particularly useful for pediatric respiratory care, where parents and caregivers often play an important role in medication management. Digital alerts can help caregivers monitor scheduled doses and treatment patterns.

With continued advances in connectivity, AI, sensors, and remote monitoring, smart inhalers are expected to contribute to a more proactive model of asthma and COPD management.